Semaglutide continues to be proven to induce medullary thyroid mobile carcinoma in rodents. While its medical relevance to individuals is unknown, the FDA advises to not administer this drug in These with a personal or relatives history of medullary thyroid carcinoma. Semaglutide also poses a chance of pancreatitis and dehydration.2013). Consistent